Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for newly diagnosed polymyalgia rheumatica
NL-OMON27507Not yet recruiting
- Sponsor
- None. This is an investigator initiated trial
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Rituximab + prednisone taper with Placebo + prednisone taper (2 arms). Primary endpoint: Glucocorticoid-free remission at week 21. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON27507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27507.